Our Team
Jeff Huber is the Founding CEO of GRAIL. GRAIL's mission is to detect cancer early, when it can be cured.
Jeff is also the Co-Founder & President of OpenCovidScreen (2020-present), a non-profit focused on catalyzing innovation in COVID-19 testing/screening that is Frequent, Fast-turnaround, Cheap, and Easy ("FFCE").
Prior to GRAIL, Jeff was a Senior Vice President at Google. Over 13 years at Google, Jeff co-founded Google's life sciences efforts in Google[x] (2013-2016), and led development and scaling for Google Maps (2011-2013), Google Apps (2005-2010), and Google Ads (2003-2011). During his tenure as an executive at Google, Jeff oversaw 50x growth in revenues (from $1 billion to >$50 billion) and organization (1,000 to >50,000 employees), and managed a $5 billion P&L and large distributed teams (5,000+ direct-line employees). Earlier, Jeff was vice president of architecture and systems development at eBay and senior vice president of engineering at Excite@Home, where he led consumer product and infrastructure development.
Jeff was recognized as one of the ‘100 Most Intriguing Entrepreneurs’ (2017), and is an active early-stage investor/advisor in breakthrough life sciences and technology companies, including Openwater, Mammoth Biosciences, LytEn, Vir, Sana, Atomwise, Genalyte, Synthego, Apexigen, Tachyon Therapeutics, Mirvie, Pinterest, Honor, OpenDoor, Bolt, and AngelList.
Jeff holds a bachelor's degree in computer engineering from the University of Illinois, where he was Commencement Speaker (2016) and received a 'Distinguished Alumni Award' from the College of Electrical & Computer Engineering (2018) for 'challenging the status quo through innovation'. He also holds a master's degree in business from Harvard University, and was a Visiting Scholar in Stanford University's Department of BioEngineering (2017-2020).
Jeff is a board member of Mammoth Biosciences, Electronic Arts (EA), Upstart (UPST), Openwater, Genalyte (Chairman), Zapata Computing, and the Parker Institute for Cancer Immunotherapy (PICI), and is a former board member of GRAIL (2016-2021; acquired for $10.1B), Aldevron (2019-2021; acquired for $9.6B), Ancestry.com (2018-2020; acquired for $4.7B), Weta Digital (2020-2021; tech assets acquired for $1.625B), and Illumina (ILMN; 2014-2016).
Jeff is an advisory board member for Stanford's Precision Health and Integrated Diagnostics Center (PHIND), Duke University's Research Translation & Commercialization (RTC) Council, and sponsors the 'Huber-Vossough Chancellor’s Chair' in Computational Biomedicine at UC Berkeley.
Steve Hochberg
Steve Hochberg has been a founder, manager, and investor in HealthTech and Healthcare companies for more than thirty years – his first company was Physicians' Online which was formed in 1991. Since 2013, Steve has been a Partner at Deerfield Management, where he has worked on structured transactions in Deerfield’s Private Funds focused on seed, growth and late stage investments in MedTech, HealthTech, and Services companies. Beginning in 2017, he launched Deerfield's first SPAC which led to the creation of AHCO. In 2018 and 2021, he co-led the launch of the firm's two Health/MedTech incubators with leading industry entrepreneurs and strategic partners.
Prior to Deerfield, Steve co-founded and co-managed Ascent Biomedical Ventures (2004) focused on early stage investment and development of biomedical companies. Steve is a founding Board Member of SLR Capital, a $8B family of BDCs (Business Development Corporations). In 2011, Steve became the Chairman of the Board of Continuum Health Partners and led its merger with Mount Sinai in 2013, where he is now a Vice Chairman of the Board of the Mount Sinai Health System, a non-profit healthcare integrated delivery system in New York City with over $7 billion in annual revenues. Steve is also a Board Member of the Cardiovascular Research Foundation. He graduated from the University of Michigan with a B.S. in Business Administration and earned his M.B.A. from Harvard Business School.
Peter Zhou is founder and portfolio manager at Hongkou Capital, a fundamental long/short hybrid equity fund which will be a part of Triatomic. Since founding Hongkou in 2021, Peter has invested in several early and late stage companies across health tech, deep tech, and AI. Between 2010 and 2020, Peter was a Senior Managing Director at Coatue Management where he managed investments across tech, healthcare, consumer, and other sectors. Previously, Peter was a private equity analyst at Blackstone, where he worked on transactions in New York, Hong Kong, and Beijing. Peter sits on the Board of Trustees of the Cancer Research Institute, one of the first backers of cancer immunotherapy research. Peter also serves on the Board of Directors of the Park Avenue Armory. Peter graduated from Harvard University in 2007 with a degree in Economics.